异动解读｜派格生物医药-B盘中上涨8.42%，牵手Rani推进代谢资产口服化持续获市场追捧

行情直击07-13

7月13日，派格生物医药-B盘中上涨8.42%，报7.47港元，成交额1.05亿港元，延续上周五大涨势头。

消息面上，公司于7月8日与美国纳斯达克上市公司Rani Therapeutics签署谅解备忘录，双方将依托Rani专有的RaniPill口服生物药递送平台，围绕派格生物肥胖症及代谢疾病管线中的多项创新候选资产开展口服制剂筛选及临床前开发，并探索相关产品在中国以外市场的研发、生产及商业化合作。该合作为公司下一代代谢管线叠加口服新剂型及海外开发路径，市场情绪持续发酵。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1103356834?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-13 09:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103356834","market":"hk","top_or_hot":-1,"title":"异动解读｜派格生物医药-B盘中上涨8.42%，牵手Rani推进代谢资产口服化持续获市场追捧","media":"行情直击","content":"<p><p>7月13日，派格生物医药-B盘中上涨8.42%，报7.47港元，成交额1.05亿港元，延续上周五大涨势头。</p><p>消息面上，公司于7月8日与美国纳斯达克上市公司Rani Therapeutics签署谅解备忘录，双方将依托Rani专有的RaniPill口服生物药递送平台，围绕派格生物肥胖症及代谢疾病管线中的多项创新候选资产开展口服制剂筛选及临床前开发，并探索相关产品在中国以外市场的研发、生产及商业化合作。该合作为公司下一代代谢管线叠加口服新剂型及海外开发路径，市场情绪持续发酵。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜派格生物医药-B盘中上涨8.42%，牵手Rani推进代谢资产口服化持续获市场追捧</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜派格生物医药-B盘中上涨8.42%，牵手Rani推进代谢资产口服化持续获市场追捧\n</h2>\n\n<h4 class=\"meta\">\n\n2026-07-13 09:45 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月13日，派格生物医药-B盘中上涨8.42%，报7.47港元，成交额1.05亿港元，延续上周五大涨势头。消息面上，公司于7月8日与美国纳斯达克上市公司Rani Therapeutics签署谅解备忘录，双方将依托Rani专有的RaniPill口服生物药递送平台，围绕派格生物肥胖症及代谢疾病管线中的多项创新候选资产开展口服制剂筛选及临床前开发，并探索相关产品在中国以外市场的研发、生产及商业化合作。该...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1103356834","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103356834","pubTimestamp":1783907137,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"7月13日，派格生物医药-B盘中上涨8.42%，报7.47港元，成交额1.05亿港元，延续上周五大涨势头。消息面上，公司于7月8日与美国纳斯达克上市公司Rani Therapeutics签署谅解备忘录，双方将依托Rani专有的RaniPill口服生物药递送平台，围绕派格生物肥胖症及代谢疾病管线中的多项创新候选资产开展口服制剂筛选及临床前开发，并探索相关产品在中国以外市场的研发、生产及商业化合作。该合作为公司下一代代谢管线叠加口服新剂型及海外开发路径，市场情绪持续发酵。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"Interpretation of the change | Paige Biomedical-B rose 8.42% intraday, joining hands with Rani to promote the oral administration of metabolic assets and continuing to be sought after by the market","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"7月13日，派格生物医药-B盘中上涨8.42%，报7.47港元，成交额1.05亿港元，延续上周五大涨势头。消息面上，公司于7月8日与美国纳斯达克上市公司Rani Therapeutics签署谅解备忘录，双方将依托Rani专有的RaniPill口服生物药递送平台，围绕派格生物肥胖症及代谢疾病管线中的多项创新候选资产开展口服制剂筛选及临床前开发，并探索相关产品在中国以外市场的研发、生产及商业化合作。该合作为公司下一代代谢管线叠加口服新剂型及海外开发路径，市场情绪持续发酵。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103356834","isCrawlerRequest":true}